-
Customized Linker Technology
One of Enzon’s core capabilities is engineering improved versions of injectable therapeutics through the chemical attachment of polyethylene glycol or PEG via a linker.
Customized Linker Technology
Enzon's PEGylation expertise includes linker chemistries designed to incorporate a stable chemical bond between the native molecule and the PEG. Enzon's Customized Linker Technology utilizes linkers designed to release the native molecule at a controlled rate. The customized linkers expand the utility of the Enzon's existing PEGylation technology, and offer a choice of releasable or permanent linkages to match each native drugs requirements. Using this technology Enzon can potentially overcome the pharmacologic limitations for a broad universe of molecules and generate compounds with substantially enhanced therapeutic value over their unmodified forms. For information about PEG partnership opportunities, please contact Enzon's business development team at partnering@enzon.com.
Search
| (ENZN) NASDAQ | |||
| Last Trade | 9.85 | ||
| Change(%) |  | +0.04 | |
| Volume | 652143 | ||
| 4:43 PM - Mar 09, 2010 | |||
News
-
09-10-2009
Enzon to Present at NewsMakers...
Enzon to Present at NewsMakers in the Biotech Industry Conference
-
07-27-2009
Enzon to Release Second Quarte...
Enzon to Release Second Quarter 2009 Earnings on Tuesday, August 4, 2009; Conference Call and Webcast to Follow
-
07-27-2009
Enzon to Present at BMO Focus...
Enzon to Present at BMO Focus on Healthcare Conference
-
07-23-2009
Enzon Enhances Governance with...
Enzon Enhances Governance with the Addition of a New Non-Executive Chairman and New Independent Director
-
04-23-2008
Cimzia®, Utilizing Enzon's PE...
Cimzia®, Utilizing Enzon's PEGylation Technology, Approved in the U.S.
-
07-02-2008
Enzon Eliminates its Remaining...
Enzon Eliminates its Remaining 2008 Debt
-
02-12-2008
Enzon Pharmaceuticals to Add N...
Enzon Pharmaceuticals to Add New Independent Director to Board
-
02-14-2008
Enzon Reports Significant Prog...
Enzon Reports Significant Progress on the Reduction of Its Debt
-
03-19-2009
Enzon Reveals New LNA Targets<...
Enzon Reveals New LNA Targets
-- Data will be presented at upcoming American Association for Cancer Research Meeting-- -
11-05-2008
Enzon Reports Solid Third Quar...
Enzon Reports Solid Third Quarter 2008 Results
-- Provides update on the sale of the specialty pharma business -- -
10-16-2008
Enzon To Present Data at EORTC...
Enzon To Present Data at EORTC-NCI-AACR
--New clinical data and LNA cancer target revealed-- -
03-17-2008
Enzon's PEG-SN38 Featured in C...
Enzon's PEG-SN38 Featured in Clinical Cancer Research